Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population.
about
Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed PatientsAtazanavir and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Patients: A Systematic ReviewIs there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration.Traditional and HIV-specific risk factors for cardiovascular morbidity and mortality among HIV-infected adults in Brazil: a retrospective cohort studyRisk of Cardiovascular Events Among Patients Initiating Efavirenz-Containing Versus Efavirenz-Free Antiretroviral RegimensInflammation, immune activation, and cardiovascular disease in HIV.Pathophysiology and management of cardiovascular disease in patients with HIVComparative effectiveness of tenofovir in treatment-naïve HIV-infected patients: systematic review and meta-analysis.Coronary Artery Disease in HIV-Infected Patients: Downside of Living Longer.Physical activity levels and perceived benefits and barriers to physical activity in HIV-infected women living in the deep south of the United States.Cardiovascular outcomes among HIV-infected veterans receiving atazanavir.Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study.Incomplete Modeling of the Effect of Antiretroviral Therapy on the Risk of Cardiovascular Events.Reply to Young et al.Recent abacavir use increases risk for Types 1 and 2 myocardial infarctions among adults with HIV.Changes in plasma lipidome following initiation of antiretroviral therapy
P2860
Q26768591-8BE4FF8C-4AEF-4C93-91C6-CFDA242A4273Q28080289-EF1090A5-1905-4AE8-AC46-B653A91E227FQ35977313-D6E7E0DB-2E9E-453E-9006-08BA9D4D4AB9Q36098224-DD2BD477-D04D-4F2E-B817-32B56DF8BE49Q36899983-0E1F423E-EF8B-420E-95B8-2A3D53B3F438Q36957752-68B5386C-4E4B-4B78-A1D7-567DEB1BF36DQ37038775-7CF71CC3-6B0F-48F2-AB51-4C808FF7424FQ38591208-7DA47CE5-4E42-4DEC-B328-59D62355E3BFQ39165028-4CE83B7F-C707-43FC-9E7F-4CC2A65A6387Q39882217-E79A945B-2C22-43C0-B277-0332BB8E0A6BQ40129344-BE72CDEC-F20C-4773-A3A8-F8623F78130FQ42609996-2FEAFC73-E641-4182-B999-C3CAD4FF0A06Q43913628-E27CA1AC-692A-48CD-8E42-E118EBD2118AQ46628528-B452396D-2DDE-467C-A39C-09C4F04195D8Q50054016-1493CC77-0590-4046-876A-35F3D140AEEFQ57167016-1FFB80A8-4166-4146-927D-DB86E706FA43
P2860
Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Risk of cardiovascular events ...... es in a US veteran population.
@ast
Risk of cardiovascular events ...... es in a US veteran population.
@en
type
label
Risk of cardiovascular events ...... es in a US veteran population.
@ast
Risk of cardiovascular events ...... es in a US veteran population.
@en
prefLabel
Risk of cardiovascular events ...... es in a US veteran population.
@ast
Risk of cardiovascular events ...... es in a US veteran population.
@en
P2093
P2860
P356
P1476
Risk of cardiovascular events ...... es in a US veteran population.
@en
P2093
Douglas K Owens
Eran Bendavid
Manisha Desai
Paul Barnett
Richard A Olshen
Vilija Joyce
P2860
P304
P356
10.1093/CID/CIV316
P407
P577
2015-04-22T00:00:00Z